Nuclera Secures $75 Million in Series C to Revolutionize Protein Access for Researchers

Nuclera, a groundbreaking biotech company committed to revolutionizing protein access for researchers, has successfully raised an impressive $75 million in its latest funding round. This capital infusion underscores the increasing demand for innovative solutions that expedite protein research, a critical component in advancing human health. At Nuclera, our mission is clear: to empower scientists by providing rapid access to high-quality, soluble, and active proteins directly at the benchtop. Our cutting-edge eProtein Discovery™ system automates the process of construct screening, yielding optimal soluble expression and purification results in less than 24 hours. By enabling protein scale-up the very next day, we significantly reduce the time and resources required for researchers to obtain reliable protein samples, often in under 48 hours. Our unique approach marries cell-free protein synthesis with digital microfluidics, delivered via smart cartridges, thus offering a high-throughput solution that accelerates progress in an array of protein projects. Founded in 2013 by visionary PhD students at the University of Cambridge, Nuclera has expanded its footprint to both Cambridge, UK, and Boston, MA, proudly employing over 100 talented professionals. This latest funding round will not only enhance our research capabilities and product development but also enable us to further our mission of making proteins accessible to ensure that scientists can "fail fast, succeed faster." With this investment, we are excited about the future of protein discovery and the impact it can have on health sciences globally.